1. Medtech Insight

People In Brief

Former Lutonix chief Dennis Wahr takes helm at Innovative Pulmonary Solutions. FDA gets two new associate commissioners. More people news.

IPS, the developer of a catheter-based procedure for treating lung diseases, has named Dennis Wahr president and CEO, according to a Sept. 20 announcement. Wahr previously co-founded drug-coated balloon angioplasty firm Lutonix, serving as president and CEO until CR Bard acquired the company in December 2011. (See Also see "Bard Buys Lutonix For Lead In Race To U.S. Market With Drug-Coated Balloon" - Medtech Insight, 2 January, 2012..) He was also the founder, president and CEO of Velocimed, maker of a patent foramen ovale closure system, which was acquired by St. Jude Medical in 2005. (See Also see "St. Jude PFO Program For Stroke, Migraine Gets Boost With Velocimed Deal" - Medtech Insight, 21 February, 2005..)

Former president and CEO Steve Dimmer will continue with Innovative Pulmonary Solutions as founder and executive vice president, while co-founder...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

HeartFlow Takes Another Crack At Public Markets With $100M IPO Filing

 
• By Marion Webb

AI heart imaging company HeartFlow filed for a $100m IPO after scrapping its 2022 SPAC plans. It remains unprofitable but is betting on FDA clearances, Medicare coverage and a demand for AI-powered diagnostics to win over investors.

FDA Document Request Denied As Case Against SurModics Merger Intensifies

 
• By Elizabeth Orr

A federal court in Illinois ruled against SurModics and BC Holdings' request for FDA documents to support a proposed merger. The FTC has challenged the merger, claiming it threatens competition in hydrophilic device coatings. The ruling may indicate the FTC is likely to succeed.

Abbott Lowers Outlook But Headwinds Are Temporary

 
• By Natasha Barrow

Despite headwinds, executives remain optimistic about growth in Abbott’s medical devices and diabetes divisions and plan several product rollouts, including the Volt PFA catheter for electrophysiology and the dual glucose-ketone sensor CGM.